Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]

BACKGROUND: New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolvi...

Descripción completa

Detalles Bibliográficos

Autores principales:	Adigweme, Ikechukwu, Akpalu, Edem, Yisa, Mohammed, Donkor, Simon, Jarju, Lamin B., Danso, Baba, Mendy, Anthony, Jeffries, David, Njie, Abdoulie, Bruce, Andrew, Royals, Michael, Goodson, James L., Prausnitz, Mark R., McAllister, Devin, Rota, Paul A., Henry, Sebastien, Clarke, Ed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472726/ https://www.ncbi.nlm.nih.gov/pubmed/36104719 http://dx.doi.org/10.1186/s13063-022-06493-5